AnaptysBio is a privately-held antibody development company advancing first-in-class programs in inflammation and immuno-oncology generated using our proprietary SHM-XEL™ platform.

Based in San Diego, AnaptysBio was founded on groundbreaking discoveries of Dr. Michael Neuberger and Dr. Matthew Scharff who elucidated the biochemistry of somatic hypermutation (SHM) and its key role in the generation of antibody diversity. AnaptysBio has pioneered the use of SHM in vitro and has succeeded in developing therapeutic antibodies where prior technologies have failed.

Multiple antibodies emanating from our pipeline are currently undergoing IND-enabling studies with potentially transformative clinical read-outs during the 2016-2017 timeframe.